Annual General Meeting 2023: IRLAB Appoints Nomination Committee

(CTN NEWS) –  IRLAB Therapeutics AB announced today the appointment of members of the nomination committee for its Annual General Meeting in 2023.

A clinical-stage biopharmaceutical company pursuing novel treatments for Parkinson’s disease’s most troubling symptoms,

Following the instruction for the appointment of the nomination committee in IRLAB Therapeutics AB passed at the annual general meeting on May 6, 2021.

The nomination committee shall consist of representatives of the three largest shareholders, or groups of shareholders, registered by Euroclear Sweden AB as of August 31, 2022. The Chair of the Board shall also be a nomination committee member.

Following the appointment of the representatives by the three largest shareholders or shareholder groups, the nominating committee for the Annual General Meeting in 2023 is made up of the following individuals:

• Hans-Peter Ostler, who has experience in banking and financial advisory, was chosen by a group of shareholders who collectively hold around 20% of the shares and the voting power;
• Anders Vedin was chosen by a group of investors representing around 14% of shares and votes, and his experience includes executive roles in major pharmaceutical businesses;
• Clas Sonesson, a founding member of IRLAB and its Chief Scientific Officer (CSO). Chosen by a group of stockholders that includes the company’s founders and who collectively hold around 9% of the shares and votes, and
• Gunnar Olsson, IRLAB Therapeutics AB’s board chair.

The owners, who collectively hold 43% of the outstanding shares and voting rights in IRLAB Therapeutics AB as of August 31, 2022, appointed the nominating committee members.

On the business website, under the heading Corporate Governance, you may find details on the nomination committee’s activities as well as instructions for the committee.

The nominating committee’s suggestion will be available on the company’s website, www.irlab.se, and in the notice for the Annual General Meeting of 2023.

By email at ir@irlab.se or postal mail at the company’s address, shareholders wishing to make ideas to the nominating committee must do so by January 31, 2023.

For more information

• Gunnar Olsson, Chair of the board
• Phone: +46 70 576 14 02
• E-mail: gunnar.olsson@irlab.se

About IRLAB

Parkinson’s disease and other CNS illnesses are the focus of IRLAB’s research and development.

Mesdopetam (IRL790) and repeat (IRL752), the company’s most advanced medication prospects, are in Phase IIb and intended to treat some of the most challenging Parkinson’s symptoms.

Ipsen, a specialty pharmaceutical firm, bought the exclusive global rights to mesdopetam’s development and marketing in 2021.

Through its unique systems biology-based Integrative Screening Process (ISP) research platform, IRLAB has created all of its drug candidates and continues to find novel therapeutic candidates for the treatment of CNS diseases.

Along with developing its robust clinical pipeline, IRLAB is moving two preclinical programs—IRL942 and IRL757—toward Phase I trials. IRLAB is a Nasdaq Stockholm-listed company. Find out more at www.irlab.se.

RELATED CTN NEWS:

France’s Orpea To Reduce Its Foreign Activities

US Wholesale Inflation Slows For 4th Straight Month To 8%